Key Takeaways
- PET/CT combines functional information from a radioactive tracer with anatomic information from CT. It is not one universal cancer scan.
- Ask for the exact tracer—such as FDG or a target-specific agent—and the clinical use: staging, treatment response, suspected recurrence, radiation planning or another defined decision.
- FDG uptake is not cancer-specific. Infection, inflammation, recent surgery, healing tissue and normal organs can appear active; some small or low-uptake tumors can be missed.
- A PET-positive site may still need biopsy, and a negative PET does not overrule pathology, suspicious CT/MRI findings or concerning symptoms.
- Preparation affects image quality. Follow the facility’s fasting, water, exercise, diabetes-medicine and blood-glucose plan precisely.
- The interval after surgery, chemotherapy, radiotherapy, immunotherapy or growth-factor injections can change interpretation. Give exact treatment dates before the appointment.
Content
Patients often hear PET/CT described as a scan that “finds cancer anywhere.” That sentence is memorable but wrong. PET/CT shows where a chosen radiotracer accumulates and aligns that signal with anatomy. Whether a bright area represents cancer depends on the tracer, tumor biology, preparation, timing and other clinical evidence.
First identify the tracer and the decision
The common oncology tracer 18F-FDG is a radioactive glucose analogue. Many cancers use glucose actively and may take up more FDG, but not all do. Other PET tracers target different biology—for example, agents aimed at PSMA-positive prostate cancer or somatostatin receptors in selected neuroendocrine tumors. NCI explains that PET radiopharmaceuticals provide metabolic or target-related information and that FDG is the most common, not the only, agent [2].
Before booking, obtain answers to:
- What tracer is ordered, including isotope and agent name?
- What cancer type and pathology does the team believe it fits?
- Is the purpose initial staging, restaging, therapy response, suspected recurrence, biopsy targeting or radiotherapy planning?
- What exact decision will change because of the result?
- Is the CT component low-dose localization, diagnostic CT, or diagnostic CT with iodinated contrast?
- Which body range is included?
“Whole-body” is not precise. Many oncology protocols scan skull base to mid-thigh; some require brain, lower limbs or a different range. The nuclear medicine team should set it according to tumor type and question.
PET, CT and contrast are three separate pieces
The PET portion detects radiation emitted from the injected tracer and provides functional information. The CT portion shows anatomy and helps localize/correct the PET signal. CT may be:
- low-dose CT mainly for attenuation correction and localization; or
- diagnostic CT with a fuller protocol, sometimes including intravenous iodinated contrast.
Do not assume a PET/CT automatically replaces a recent diagnostic contrast CT. Conversely, do not assume the CT portion always adds the same radiation or requires iodine. Ask what is planned.
If iodinated contrast is included, kidney function, metformin instructions and prior contrast reactions need the separate CT-contrast review. A radiotracer injection is not the same as iodinated CT contrast.
Preparation is part of the measurement
For a typical FDG oncology study, the facility may ask the patient to:
- fast for a specified period, commonly several hours;
- drink only plain water during that period;
- avoid strenuous exercise for about 24 hours;
- avoid sugar-containing drinks, gum and unnecessary talking or chewing around the uptake period;
- stay warm, quiet and relaxed after injection;
- empty the bladder before imaging.
SNMMI/EANM guidance uses a 4–6 hour fast, encourages plain water and recommends avoiding vigorous exercise for 24 hours because food, insulin and muscle activity can redirect FDG uptake [5]. Follow the actual center’s written instruction rather than combining rules from several websites.
Tell staff if the patient ate, exercised, felt cold/shivered, received glucose-containing IV fluid, used insulin at a different time, or could not rest quietly. These details may create uptake patterns that matter during interpretation.
Diabetes needs a scheduled plan, not a longer fast
High blood glucose and recent insulin can compete with or redistribute FDG. Patients with diabetes should not simply skip food and medicine for as long as possible. Ask the nuclear medicine unit:
- preferred appointment time;
- allowed glucose range and when it will be checked;
- last meal composition and time;
- timing of insulin, tablets and pump changes;
- what happens if glucose is above the center’s threshold;
- how to treat hypoglycemia without concealing it.
Do not take an unplanned correction dose immediately before the scan. Do not hide food or insulin use to preserve the booking. Rescheduling may be safer and more informative than producing an uninterpretable study.
Give every recent treatment and inflammation date
FDG also accumulates in activated immune cells and healing tissue. Tell the interpreting team about:
- biopsy or surgery, with site and date;
- radiotherapy field and final date;
- chemotherapy, targeted therapy or immunotherapy dates;
- colony-stimulating/growth-factor injections;
- vaccination site and date;
- recent infection, fever, inflammatory disease or trauma;
- new pain, wounds or dental procedures.
The correct waiting interval is not one universal number. It depends on the therapy, cancer and question. A scan intended to assess response after radiotherapy is timed differently from urgent staging before treatment. Immunotherapy can also produce inflammatory patterns that need appropriate response criteria. Let the oncology and nuclear medicine teams choose the date.
What happens during the visit
After identity, pregnancy and glucose checks, a small amount of radiotracer is injected. The patient then rests during an uptake period, often around an hour, before lying still on the scanner table. The acquisition itself may take tens of minutes; total time is longer because preparation and uptake are included [1].
Report injection-site pain or swelling immediately. Tracer outside the vein can affect image quality and dose distribution. China’s 2025 nuclear-medicine quality indicators specifically monitor radiopharmaceutical extravasation and require PET/CT reports to document the tracer, injection, uptake time, scan range, CT parameters, comparisons and relevant findings [6].
The scanner is a short tunnel/ring similar in appearance to CT. Tell the unit ahead of time about severe claustrophobia, inability to lie flat, uncontrolled pain or movement. Do not assume sedation is available without a separate plan.
A “hot spot” is not a pathology report
FDG uptake can occur in tumor, infection, inflammation, healing muscle, brown fat and normal organs. Recent surgery or radiation can create activity. NCI’s lung-cancer evidence, for example, describes false-positive FDG uptake in enlarged lymph nodes from inflammation or infection and supports tissue confirmation in relevant settings [4].
Interpretation should combine:
- uptake pattern and intensity;
- lesion size and CT appearance;
- known physiologic distribution;
- comparison with prior PET/CT, CT or MRI;
- treatment and infection timing;
- pathology and tumor biology.
SUV is a semi-quantitative value, not a universal cancer meter. It is affected by uptake time, glucose, body composition, scanner/reconstruction, injected activity and region-of-interest method. Do not compare an SUV from two centers as if it were a laboratory test unless acquisition and analysis are sufficiently comparable.
Why PET can miss cancer
False-negative results can occur when a lesion is very small, has low tracer avidity, lies near an organ with high normal uptake, is blurred by movement, or is affected by high blood glucose or treatment. Some tumor types and subtypes are not reliably FDG-avid. Brain, urinary tract and other high-background areas require special interpretation.
Therefore:
- PET does not replace a diagnostic-quality CT or MRI when those answer the anatomy better;
- PET does not replace endoscopy or organ-specific screening;
- PET does not establish tumor grade or biomarkers;
- PET does not eliminate the need for biopsy when tissue will determine diagnosis or treatment.
NCI states that there is no single test that diagnoses cancer and that biopsy is often the only way to be certain [3]. A negative PET must be reconciled with pathology and suspicious conventional imaging, not used to erase them.
Radiation and people nearby
PET/CT involves radiation from both the radiotracer and CT. The amount varies with tracer activity, patient size, CT protocol and scan range. The test should be justified by a specific clinical purpose and optimized, especially in children and people needing repeated imaging.
Tell the unit before injection if the patient is pregnant, may be pregnant or is breastfeeding. Nuclear medicine staff must decide whether to postpone, use another modality or provide tracer-specific breastfeeding and contact instructions. Do not apply a generic “stay away for 24 hours” rule: the agent and administered activity matter.
After an FDG study, the facility may advise hydration, frequent urination, hand hygiene and temporary distance from pregnant people or small children. Obtain the exact duration in writing before leaving.
China’s National Health Commission prohibits using PET/CT as a routine health-check tool, reflecting the need for clinical justification, radiation protection and cost control [7]. This does not limit its appropriate use for a defined cancer question.
Make the report comparable across borders
A useful PET/CT package should include:
- indication and relevant pathology;
- tracer name and administered activity;
- injection and scan times;
- blood glucose before injection;
- scan range and CT protocol, including iodine contrast if used;
- comparison study dates;
- lesion location, size, uptake description and CT correlation;
- full DICOM PET, CT and fused series;
- final report and follow-up recommendation.
China’s current nuclear medicine quality indicators list these elements as part of report completeness [6]. If response assessment is the goal, try to use a comparable tracer, preparation, uptake interval and protocol. Send the previous DICOM—not merely the prior SUV table.
Medical disclaimer: This guide provides general education. PET/CT indication, tracer, preparation, timing, radiation precautions and interpretation must be individualized by oncology and nuclear medicine professionals.
FAQ
Does a PET-positive lymph node prove metastasis?
No. Infection and inflammation can also be PET-positive. The location, CT appearance, timing and cancer type matter, and biopsy may still be required if the result changes treatment.
Does a negative PET mean there is no cancer?
No. Small or low-uptake tumors and lesions near high-background organs can be missed. The result must be reconciled with pathology, CT/MRI and symptoms.
Why must I avoid exercise before FDG PET/CT?
Active muscles take up glucose and may also take up FDG, creating distracting activity. Follow the center’s exact exercise restriction, commonly about 24 hours for vigorous exercise.
Can a patient with diabetes have PET/CT?
Yes, but appointment time, meals, insulin/tablets and glucose targets need a coordinated plan. Do not independently prolong fasting or take an unplanned correction dose.
Is the CT in PET/CT a full diagnostic CT?
Not always. It may be low-dose CT used mainly for localization, or a diagnostic CT with a separate protocol and possibly iodinated contrast. Ask which one is ordered.
Sources
- RadiologyInfo (ACR/RSNA): PET/CT
- US National Cancer Institute: CT and Combined PET/CT in Cancer
- US National Cancer Institute: Tests and Procedures Used to Diagnose Cancer
- US National Cancer Institute: FDG-PET False Positives and Tissue Confirmation in Lung Cancer
- SNMMI/EANM: FDG PET/CT Guidelines for Tumor Imaging
- National Health Commission of China: Nuclear Medicine Quality Indicators (2025)
- National Health Commission of China: Why PET/CT Is Not a Routine Health Examination